Publicaciones en las que colabora con Sandra Blasco Benito (12)

2024

  1. Fatty acid amide hydrolase drives adult mammary gland development by promoting luminal cell differentiation

    Cell Death Discovery, Vol. 10, Núm. 1

2023

  1. Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

    Nature Communications, Vol. 14, Núm. 1

  2. Neuronal Cannabinoid CB1 Receptors Suppress the Growth of Melanoma Brain Metastases by Inhibiting Glutamatergic Signalling

    Cancers, Vol. 15, Núm. 9

2022

  1. An optimized MNK1b aptamer, apMNKQ2, and its potential use as a therapeutic agent in breast cancer

    Molecular Therapy - Nucleic Acids, Vol. 30, pp. 553-568

2019

  1. Therapeutic targeting of HER2–CB 2 R heteromers in HER2-positive breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 9, pp. 3863-3872

  2. Erratum: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (3863–3872) DOI: 10.1073/pnas.1815034116)

    Proceedings of the National Academy of Sciences of the United States of America

2018

  1. Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer

    Biochemical Pharmacology, Vol. 157, pp. 285-293

2016

  1. Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer

    Oncotarget, Vol. 7, Núm. 30, pp. 47565-47575

2015

  1. New inhibitors of angiogenesis with antitumor activity in vivo

    Journal of Medicinal Chemistry, Vol. 58, Núm. 9, pp. 3757-3766

  2. Role of cannabinoid receptor CB<inf>2</inf> in HER2 pro-oncogenic signaling in breast cancer

    Journal of the National Cancer Institute, Vol. 107, Núm. 6

  3. Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer

    Journal of Medicinal Chemistry, Vol. 58, Núm. 5, pp. 2256-2264

2014

  1. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling

    Journal of Biological Chemistry, Vol. 289, Núm. 32, pp. 21960-21972